JNCI Vol. 102, Issue 9
May 5, 2010
(44). Here, we show that the mode of detection and the bio-
markers p16, COX-2, and Ki67 may be used to help stratify a
woman’s risk of subsequent invasive cancer and to help
her decide whether she should undergo adjuvant therapies. In
addition, these factors may provide insight for targeted
1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of DCIS in
women undergoing screening mammography. J Natl Cancer Inst.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and
ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168–183.
3. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with
lumpectomy and radiation therapy for the treatment of intraductal breast
cancer. N Engl J Med. 1993;328(22):1581–1586.
4. Fisher B, Land S, Mamounas E, Dignam J, Fisher E, Wolmark N.
Prevention of invasive breast cancer in women with ductal carcinoma in
situ: an update of the national surgical adjuvant breast and bowel project
experience. Semin Oncol. 2001;28(4):400–418.
5. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with
recurrence among women with ductal carcinoma in situ treated by lump-
ectomy. J Natl Cancer Inst. 2003;95(22):1692–1702.
6. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving
treatment for ductal carcinoma in situ: ﬁrst results of the EORTC ran-
domised phase III trial 10853. Lancet. 2000;355(9203):528–533.
7. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation
therapy for the treatment of intraductal breast cancer: ﬁndings from na-
tional surgical adjuvant breast and bowel project B-17. J Clin Oncol.
8. Warren JL, Weaver DL, Bocklage T, et al. The frequency of ipsilateral
second tumors after breast-conserving surgery. Cancer. 2005;104(9):
9. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intra-
ductal breast cancer National Surgical Adjuvant Breast and Bowel Project
B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.
10. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PIthe consen-
sus Conference Committee. The consensus conference on the treatment
of in situ ductal carcinoma of the breast. Cancer. 2000;88(4):946–954.
11. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Barbash R. Mortality
among women with ductal carcinoma in situ of the breast in the popula-
tion-based SEER Program. Arch Intern Med. 2000;160(7):953–958.
12. Solin L, Fourquet A, Vicini F, et al. Long-term outcome after breast-
conservation treatment with radiation for mammographically detected
ductal carcinoma in situ of the breast. Cancer. 2005;103(6):1137–1146.
13. Ringberg A, Nordgren H, Thorstensson S, et al. Histopathological risk
factors for ipsilateral breast events after breast conserving treatment for
ductal carcinoma in situ of the breast—results from the Swedish ran-
domised trial. Eur J Cancer. 2007;43(2):291–298.
14. Silverstein MJ. Ductal carcinoma in situ of the breast: 11 reasons to con-
sider treatment with excision alone. Womens Health. 2008;4(6):565–577.
15. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M. Cell biolog-
ical factors in ductal carcinoma in situ (DCIS) of the breast-relationship
to ipsilateral local recurrence and histopathological characteristics. Eur J
16. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE.
Biological markers that predict clinical recurrence in ductal carcinoma in
situ of the breast. Eur J Cancer. 2003;39(5):622–630.
17. Cornﬁeld DB, Palazzo JP, Schwartz GF, et al. The prognostic signiﬁ-
cance of multiple morphologic features and biologic markers in ductal
carcinoma in situ of the breast. Cancer. 2004;100(11):2317–2327.
18. Roka S, Rudas M, Taucher S, et al. High nuclear grade and negative
estrogen receptor are signiﬁcant risk factors for recurrence in DCIS. Eur
J Surg Oncol. 2004;30(3):243–247.
19. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.
Absence of HER4 expression predicts recurrence of ductal carcinoma in
situ of the breast. Clin Cancer Res. 2005;11(6):2163–2168.
20. Barnes N, Haywood P, Knox WF, Bundred NJ. Survivin expression in in
situ and invasive breast cancer relates to COX-2 expression and DCIS
recurrence. Br J Cancer. 2006;94(2):253–258.
21. Gauthier M, Pickering C, Miller C, et al. p38 regulates cyclooxygenase-2
in human mammary epithelial cells and is activated in premalignant tissue.
Cancer Res. 2005;65(5):1792–1799.
22. Gauthier ML, Berman HK, Miller C, et al. Abrogated stress response
distinguishes basal-like tumors and DCIS lesions associated with subse-
quent tumor events. Cancer Cell. 2007;12(5):479–491.
23. Tamimi R, Baer H, Marott J, et al. Comparison of molecular phenotypes
of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res.
24. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive
factors in breast cancer by immunohistochemical analysis. Mod Pathol.
25. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and
survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of
a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
27. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability
curves in summarizing competing risks failure time data? Stat Med.
28. Allred D, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence
of diversity during breast cancer evolution. Clin Cancer Res. 2008;
29. Bryan B, Schnitt S, Collins L. Ductal carcinoma in situ with basal-like
phenotype: a possible precursor to invasive basal-like breast cancer. Mod
30. Dabbs D, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal
carcinoma in situ: recognition and immunohistologic proﬁle. Mod Pathol.
31. Livasy C, Perou C, Karaca G, et al. Identiﬁcation of a basal-like subtype
of breast ductal carcinoma in situ. Hum Pathol. 2007;38(2):197–204.
32. Subhawong A, Subhawong T, Nassar H, et al. Most basal-like breast
carcinomas demonstrate the same Rb-/p16+ immunophenotype as the
HPV-related poorly differentiated squamous cell carcinomas which they
resemble morphologically. Am J Surg Pathol. 2008;33(2):163–175.
33. Herschkowitz J, He X, Fan C, Perou C. The functional loss of the retino-
blastoma tumour suppressor is a common event in basal-like and luminal
B breast carcinomas [published online ahead of print September 9, 2008].
Breast Cancer Res. 2008;10(5):R75.
34. Crawford YG, Gauthier ML, Joubel A, et al. Histologically normal
human mammary epithelia with silenced p16(INK4a) overexpress COX-2,
promoting a premalignant program. Cancer Cell. 2004;5(3):263–273.
35. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2
in epithelial-stromal cell interactions and progression of ductal carcinoma
in situ of the breast. Proc Natl Acad Sci U S A. 2009;106(9):3372–3377.
36. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer
metastasis to lung. Nature. 2005;436(7050):518–524.
37. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in
2282 patients with breast carcinoma. World J Surg. 2001;25(6):767–772.
38. Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on out-
come in patients with ductal carcinoma-in-situ treated with breast-con-
serving therapy. J Clin Oncol. 2000;18(2):296–306.
39. Wells WA, Carney PA, Eliassen MS, Grove MR, Tosteson ANA.
Pathologists’ agreement with experts and reproducibility of breast ductal
carcinoma-in-situ classiﬁcation schemes. Am J Surg Pathol. 2000;
40. Douglas-Jones AG, Morgan JM, Appleton MAC, et al. Consistency in the
observation of features used to classify duct carcinoma in situ (DCIS) of
the breast. J Clin Pathol. 2000;53(8):596–602.
41. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving
surgery and deﬁnitive breast irradiation for the treatment of ductal carci-
noma in situ of the breast. J Clin Oncol. 1996;14(3):754–763.
42. Solin LJ, Fourquet A, Vicini FA, et al. Mammographically detected ductal
carcinoma in situ of the breast treated with breast-conserving surgery and
deﬁnitive irradiation: long-term outcome and prognostic signiﬁcance of